Side effects might include God –
Nov. 4, 2020 – Over the last few years promising preliminary research has shown psilocybin to potentially be effective in helping terminal cancer patients manage end of life anxiety. Initial psilocybin trials focusing on depression concentrated specifically on treatment-resistant depression – a clinical classification that categorizes patients suffering from MDD who have not responded effectively to at least two different pharmacological antidepressant treatments during a current depressive episode.
MDD is much more common, with some estimates suggesting over 300 million people worldwide suffer from the debilitating condition. While a larger Phase 2 trial testing psilocybin for MDD is currently underway, this new study, in the journal JAMA Psychiatry, offers the first peer-reviewed published data showing efficacy for this particular mental health condition.